Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Bipolar Disorder
Interventions
DRUG

Aripiprazole

Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.

DRUG

Placebo

Tablets, Oral, 0 mg, Once daily, 8 weeks.

Trial Locations (28)

Unknown

Local Institution, Tuscaloosa

Local Institution, Little Rock

Local Institution, San Diego

Local Institution, Sherman Oaks

Local Institution, Norwich

Local Institution, West Haven

Local Institution, Jacksonville

Local Institution, Maitland

Local Institution, Orlando

Local Insstitution, Honolulu

Local Institution, Chicago

Local Institution, Lake Charles

Local Institution, Rockville

Local Institution, Durham

Local Institution, Raleigh

Local Institution, Beachwood

Local Institution, Dayton

Local Institution, Oklahoma City

Local Institution, Portland

Local Institution, Media

Local Institution, Memphis

Local Institution, Austin

Local Institution, Dallas

Local Institution, Houston

Local Institution, Lake Jackson

Local Institution, Wichita Falls

Local Institution, Arlington

Local Institution, Bellevue

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00080314 - Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode | Biotech Hunter | Biotech Hunter